The ImproveCareNow Registry: Prediction of different remission rates in pediatric ulcerative colitis

Abstract Objectives Identifying predictors of clinical remission in pediatric ulcerative colitis (UC) will impact the therapeutic approach. We aimed to predict time to first (TFR), corticosteroid‐free (TCSFR, ≥3 months corticosteroid withdrawal), and sustained remission (TSR, ≥6 months). Methods This retrospective study analyzed de‐identified prospectively collected data from 2383 patients enrolled in ImproveCareNow (2007–2023). We included UC patients under 18 years at diagnosis. Remission was defined as a Pediatric UC Activity Index (PUCAI; <10 points). The Statistical Package for the Social Sciences version 29 with multiple imputation for missing data was used for statistical analysis. Cox regression identified predictors at diagnosis/enrollment (T0) or first visit (T1) on the outcomes ( n = 1785). This study received ethics committee approval (23135‐ICN_UC). Results Mean TFR was 177.7 days, predicted by disease extent ( p > 0.05) at T0 and history of severe UC (hazard ratio [HR] = 1.142, p = 0.05) before inclusion. In patients not reaching remission at T1 (subgroup; n = 964), TFR was predicted by PUCAI (confounder; moderate HR = 0.867 or severe disease HR = 0.697, p < 0.1) at T1 and history of severe UC (HR = 1.292, p = 0.007) before T1 (mean 25 days SEM 0.7). Mean TCSFR was 569.6 days, predicted by PUCAI (only mild HR = 0.728 and moderate HR = 0.559, p < 0.001) and use of corticosteroids (HR = 0.668, p < 0.001) at T1 (mean 32 days SEM 0.9). Mean TSR was 631.0 days, predicted by PUCAI (only mild HR = 0.721 and moderate HR = 0.541, p < 0.001) and the use of oral aminosalicylates (HR = 0.793, p = 0.003) at T1 (mean 30 days SEM 0.7). Conclusions Several clinical parameters in early disease course predict remission with increasing PUCAI as useful negative predictor.

Authors

Institutions

Publication Details

Journal
JPGN Reports
Published
2026-09-14
DOI
https://doi.org/10.1002/jpr3.70234
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

The ImproveCareNow Registry: Prediction of different remission rates in pediatric ulcerative colitis

Elisabeth De Greef, Shehzad A. Saeed, Lucas Wauters, Koen Huysentruyt et al.
JPGN Reports
Inflammatory Bowel Disease
article

The ImproveCareNow Registry: Prediction of different remission rates in pediatric ulcerative colitis

Elisabeth De Greef, Shehzad A. Saeed, Lucas Wauters, Koen Huysentruyt, Jonathan Van Hecke, Jeremy Adler, Gigi Veereman, and the ImproveCareNow Pediatric IBD Learning Health System
article en

Abstract

Abstract Objectives Identifying predictors of clinical remission in pediatric ulcerative colitis (UC) will impact the therapeutic approach. We aimed to predict time to first (TFR), corticosteroid‐free (TCSFR, ≥3 months corticosteroid withdrawal), and sustained remission (TSR, ≥6 months). Methods This retrospective study analyzed de‐identified prospectively collected data from 2383 patients enrolled in ImproveCareNow (2007–2023). We included UC patients under 18 years at diagnosis. Remission was defined as a Pediatric UC Activity Index (PUCAI; <10 points). The Statistical Package for the Social Sciences version 29 with multiple imputation for missing data was used for statistical analysis. Cox regression identified predictors at diagnosis/enrollment (T0) or first visit (T1) on the outcomes ( n = 1785). This study received ethics committee approval (23135‐ICN_UC). Results Mean TFR was 177.7 days, predicted by disease extent ( p > 0.05) at T0 and history of severe UC (hazard ratio [HR] = 1.142, p = 0.05) before inclusion. In patients not reaching remission at T1 (subgroup; n = 964), TFR was predicted by PUCAI (confounder; moderate HR = 0.867 or severe disease HR = 0.697, p < 0.1) at T1 and history of severe UC (HR = 1.292, p = 0.007) before T1 (mean 25 days SEM 0.7). Mean TCSFR was 569.6 days, predicted by PUCAI (only mild HR = 0.728 and moderate HR = 0.559, p < 0.001) and use of corticosteroids (HR = 0.668, p < 0.001) at T1 (mean 32 days SEM 0.9). Mean TSR was 631.0 days, predicted by PUCAI (only mild HR = 0.721 and moderate HR = 0.541, p < 0.001) and the use of oral aminosalicylates (HR = 0.793, p = 0.003) at T1 (mean 30 days SEM 0.7). Conclusions Several clinical parameters in early disease course predict remission with increasing PUCAI as useful negative predictor.

JPGN Reports
Vrije Universiteit Brussel (BE), Wright State University (US), University of Michigan (US), Michigan Medicine (US), KU Leuven (BE)
Reduced inequalities
Openalex Percentile: Top 11%
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.